562840-53-3Relevant academic research and scientific papers
Metabolic investigation on ZL006 for the discovery of a potent prodrug for the treatment of cerebral ischemia
Chen, Dongyin,Zhao, Ting,Ni, Kaidong,Dai, Peng,Yang, Lei,Xu, Yi,Li, Fei
, p. 2152 - 2155 (2016)
4-((3,5-Dichloro-2-hydroxybenzyl)amino)-2-hydroxybenzoic acid (ZL006, 1) is a small-molecular inhibitor of the nNOS/PSD-95 interaction, that is under preclinical evaluation stage for cerebral ischemia. However, the fast metabolism and low permeability acr
As neuroprotective agents of pharmaceutical compounds
-
, (2019/06/26)
The invention discloses a medicinal compound as a neuroprotective agent. The medicinal compound is a neuronal nitric oxide synthase-postsynaptic density protein 95 (nNOS-PSD95) decoupling agent. The medicinal compound is a benzene ring derivative shown in the general formula (I) or its pharmaceutically acceptable salt. The invention further discloses a preparation method of the medicinal compound and a use of the medicinal compound in prevention and treatment on neuronal damage influence-caused diseases.
Mesoionic pyrido[1,2-a]pyrimidinones: Discovery of dicloromezotiaz as a lepidoptera insecticide acting on nicotinic acetylcholine receptors1,2
Zhang, Wenming,Holyoke, Caleb W.,Barry, James,Cordova, Daniel,Leighty, Robert M.,Tong, My-Hanh T.,Hughes, Kenneth A.,Lahm, George P.,Pahutski, Thomas F.,Xu, Ming,Briddell, Twyla A.,McCann, Stephen F.,Henry, Yewande T.,Chen, Yuzhong
, p. 911 - 917 (2017/02/10)
A novel class of mesoionic pyrido[1,2-a]pyrimidinones has been discovered with exceptional insecticidal activity controlling a number of insect species. In this communication, we report the part of the optimization program that led to the identification o
